Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

RFI Lupus Research Program (LRP) Public

Active
HT9427RFI2027LRPFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027LRP to gather feedback for the Lupus Research Program. This initiative aims to inform future focus areas and research funding opportunities for fiscal year 2027. The program is specifically seeking input from academia, industry, non-profit organizations, federal agencies, and the general public to identify critical gaps in the field and underfunded research areas. Strategic goals include improving the quality of life for patients, gaining insight into disease mechanisms and heterogeneity, and advancing the understanding of lupus patient subsets to optimize treatment. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. Consequently, no contract will be awarded based on this announcement, and there are no established deliverables or periods of performance. Interested parties are requested to provide their feedback via Survey Monkey by November 16, 2026, at 4:00 PM EST. While previous appropriations from fiscal years 2017 through 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated.

General Info

DHA seeks feedback on future research priorities for the 2027 Lupus Research Program.

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Frederick, MD, 21702, USA

Set-Aside

NONE

Documents

2

FY27 Lupus Research Program (LRP) RFI

DOCX, Low priorityrfi
Low

Lupus Research Program (LRP) Public Request for Information - FY27

DOCX, Low priorityrfi
Low

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSources Sought
Posted

Sources Sought

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency
Contacts1 person available
OfficeFORT DETRICK, MD, 21702, USA
Office AddressFORT DETRICK, MD, 21702, USA

Full Description

Show more

The Congressionally Directed Medical Research Programs (CDMRP) seeks feedback to inform potential future Lupus Research Program (LRP) focus areas and associated research funding opportunities. 


Although fiscal year 2027 (FY27) funds have not been appropriated, the LRP is requesting this information to support program planning processes.  The CDMRP wants to hear from all audiences, interested parties, and individuals from academia, industry, community and non-profit organizations, scientific and professional organizations, federal agencies, and the public. 


This RFI is for information and planning purposes only and should not be construed as a solicitation or an obligation on the part of the LRP or the Department of War.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Grant
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-024
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
Solicitation # RFA-RM-27-007
The National Institutes of Health, under the Department of Health and Human Services, is soliciting the development or adaptation of innovative senescence technologies (SenTecs) through solicitation RFA-RM-27-007. These technologies aim to identify, characterize, and understand senescent cell heterogeneity within tissue environments and secretomes to improve strategies for modulating these cells in human aging and disease. The program utilizes a five-year, milestone-driven award structure divided into two phases: a two-year UG3 phase focused on development and feasibility, and a three-year UH3 phase dedicated to optimization, refinement, and validation. Transition to the UH3 phase is not automatic and requires an administrative review at the end of year two. The final year of the award requires a collaborative demonstration project within the SenNet consortium. The NIH intends to commit 5.4 million dollars in total costs for fiscal year 2027 to fund up to nine awards, with direct cost caps of 400,000 dollars per year for the UG3 phase and 550,000 dollars per year for the UH3 phase. Applications are evaluated based on the importance of the research, scientific rigor, feasibility, and the expertise of the investigators. Required submissions include an Intellectual Property Strategy and a Data Management and Sharing Plan. Awardees must adhere to strict cybersecurity incident reporting, maintain a seven-year confidentiality agreement for non-public information, and ensure all technical assets and data are deposited into the SenNet Data Portal. Clinical trials are not allowed under this specific opportunity.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
Solicitation # RFA-HG-27-008
The National Human Genome Research Institute (NHGRI), under the Department of Health and Human Services, is soliciting applications for the Impact of Genomic Variation on Function (IGVF) Data and Coordinating Center (DACC) via solicitation RFA-HG-27-008. The DACC will serve as the central hub for the IGVF Consortium, tasked with developing a comprehensive, searchable catalog of genomic function and variant impacts and managing a data portal for housing and sharing consortium resources. Key technical objectives include the hardening of data processing pipelines to ensure they are containerized, robust, and reproducible, while adopting existing data and metadata standards to promote interoperability. The NHGRI intends to commit 6 million dollars in total costs for the period of FY 2027-2031, with annual application budgets limited to 4 million dollars in direct costs. Funding decisions are based on scientific peer review and program-specific considerations, focusing on technical merit, synergy with other IGVF projects, and the applicant's capability to coordinate large-scale genomic data efforts. Applicants must maintain active registrations in SAM, eRA Commons, and Grants.gov, and all Principal Investigators must have a linked ORCID ID. Special requirements include a dedicated Project Manager devoting at least 6 person months and strict adherence to the Cybersecurity Act of 2015, which mandates reporting cybersecurity incidents within 48 hours of discovery. Proposals must include a Research Strategy limited to 30 pages and be submitted via an institutional system-to-system solution by the December 14, 2026, deadline.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-RM-27-016
The National Institutes of Health (NIH) is soliciting applications under RFA-RM-27-016 to establish SenNet Discovery and Validation Centers (DVCs) as part of Stage 2 of the Cellular Senescence Network. The primary objective of these centers is to define, refine, and validate tissue- and disease-relevant cellular senescence signatures, known as senotypes, and their associated biomarkers. DVCs are required to investigate the functional consequences of these signatures in human health and disease, generate high-quality molecular, cellular, and spatial datasets for public release via the Data Coordination and Informatics Center, and execute consortium-wide organizational and outreach activities. The maximum project period is five years, with application budgets limited to approximately 3 million dollars in direct costs per year. A specific requirement includes a mandatory 600,000 dollar annual direct cost allocation for the SenNet Organization and Outreach Component, of which 40 to 45 percent must support educational programs. Additionally, starting in Year 2, centers must set aside approximately 10 percent of their total budget for cross-consortium validation. Applications are evaluated through the NIH peer review system based on significance, approach, and the protection of human subjects, with performance measured annually by the successful acceptance and public release of data. Applicants must maintain active registrations in the System for Award Management and eRA Commons. Required submission materials include a 30-page application divided into four elements covering vision, preclinical modeling, biospecimen management, and outreach, along with letters of support and human subjects documentation where applicable. Awardees must adhere to strict data security protocols, including a seven-year confidentiality disclosure agreement and a requirement to report cybersecurity incidents within 48 hours.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
Solicitation # RFA-HG-27-007
The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications under RFA-HG-27-007 to establish centers for the Impact of Genomic Variation on Function (IGVF) Consortium. The primary objective is to characterize genomic variation and assess how individual variants in DNA, RNA, or protein-coding elements impact genome function and phenotypes. Funded centers will utilize high-throughput methods to perturb variants, collect molecular and cellular data, and develop portable data processing pipelines. These centers are expected to collaborate within the consortium to coordinate assays and cell types, contributing raw and processed data to the IGVF Catalog via the Data Analysis and Coordination Center. The funding cycle runs from 2027 through fiscal year 2031, with a maximum project period of five years and budgets limited to 2 million dollars in direct costs per year. Notably, 20 percent of direct costs must be allocated to support collaborative work. Applications are evaluated based on scientific merit through the NIH peer review system and a second level of review by the National Advisory Council for Human Genome Research, focusing on significance, overall impact, and the utility of the proposed assays. Clinical trials are not allowed, and research involving human subjects must comply with 45 CFR Part 46. Applicants must maintain active registrations in the System for Award Management and eRA Commons, and all Principal Investigators must have a linked ORCID ID. Required submissions include a Research Strategy limited to 30 pages, a Resource Sharing Plan, and a Data Management and Sharing Plan. Key personnel requirements include a minimum of three person-months of effort for the PD/PI and a dedicated Project Manager committing at least four person-months. Additionally, awardees must implement a cybersecurity incident response plan with a 48-hour notification requirement for any discovered incidents.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in 2 months
View Details

More opportunities from Department Of Defense → Defense Health Agency

Same awarding agency

NAICS: 811210
New
Federal
Steris Sterilizer Maintenance/Service at Offutt AFB, NE
Solicitation # HT940726Q0001
The Defense Health Agency Contracting Activity Central Division is soliciting quotations for a single-award, Firm-Fixed-Price commercial service contract to provide comprehensive maintenance and repair services for Government-owned Steris sterilization and washer equipment. Located at the 55th Medical Group, Ehrling Bergquist Clinic at Offutt Air Force Base, Nebraska, the scope of work includes scheduled preventive maintenance, safety inspections, calibrations, annual chamber cleanings, and unscheduled emergency repairs. Covered equipment consists of three Steris AMSCO 400 Steam Sterilizers, one Steris Reliance Vision Single Chamber Washer Disinfector, two Steris AMSCO 7052HP Single Chamber Washer Disinfectors, and two Steris IWECO5 Ultrasonic Instrument Washers. Services must be performed by certified technicians using genuine OEM or approved equivalent parts. This procurement is a 100 percent Total Small Business Set-Aside under NAICS 811210 and 811211. The anticipated period of performance includes one 12-month base period, four 12-month option periods, and a potential six-month extension, running from November 1, 2026, through April 30, 2032. Award will be determined using the Lowest Price Technically Acceptable (LPTA) method, with the Total Evaluated Price encompassing the base period, all option years, and the six-month extension. Technical acceptability is based on a pass/fail evaluation of the contractor's personnel qualifications, OEM resource access, and ability to meet a 48-business-hour emergency response standard and a 95 percent monthly equipment uptime requirement. Quotations are due electronically by October 19, 2026, at 2:00 PM Eastern Time.
Electronic and Precision Equipment Repair and Maintenance

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 541715
New
Federal
MTEC Solicitation Summary: Fiscal Year 2026 Multi-Topic Request for Project Proposals
Solicitation # MTEC-26-04-MultiTopic
The Medical Technology Enterprise Consortium (MTEC), in collaboration with the Defense Health Agency, is soliciting project proposals under solicitation MTEC-26-04-MultiTopic for medical prototype technological and knowledge solutions. Authorized under 10 U.S.C. section 4022 and utilizing an Other Transaction Agreement, this effort seeks to modernize medical capabilities to maintain force readiness and soldier lethality in future multi-domain conflicts. The solicitation covers 16 distinct Focus Areas, including behavioral health, physical fitness, wound infection prevention, sepsis treatment, musculoskeletal injury interventions, non-addictive analgesics, blast and blunt impact sensors, and a multisite clinical biomarker platform for lung and kidney failure. Proposals are submitted via a two-stage Enhanced White Paper process, where selected Stage 1 submissions are invited to provide full cost proposals in Stage 2. To be eligible, projects must demonstrate clear military relevance, meet a minimum Knowledge/Technology Readiness Level of 3, and fit the specific definition of a prototype rather than being exploratory. Additionally, solutions must not have been submitted to MTEC within the last two years. While average initial awards range from 2.0 to 3.5 million dollars over a two to three year period, specific funding and performance periods vary by Focus Area. Teaming is encouraged, and successful projects may be eligible for non-competitive follow-on tasks.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

5 days ago

DEADLINE

in 16 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS